Search all medical codes

Injection, polatuzumab vedotin-piiq, 1 mg

HCPCS code

Name of the Procedure:

Common Name: Injection of Polatuzumab Vedotin
Technical Term: Injection, polatuzumab vedotin-piiq, 1 mg (HCPCS J9309)

Summary

Injection of Polatuzumab Vedotin is a medical treatment involving the administration of a drug used primarily for certain types of cancer. It's a targeted therapy designed to attack cancer cells.

Purpose

Medical Conditions: This treatment is mainly used for aggressive forms of B-cell lymphoma, such as diffuse large B-cell lymphoma (DLBCL).
Goals: The goal is to reduce the size of the cancer, alleviate symptoms, and possibly achieve remission.

Indications

Symptoms/Conditions: Patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Criteria: Suitable for adult patients who have already tried other treatments without success.

Preparation

Instructions: Patients might be advised to avoid certain medications, follow dietary restrictions, or hydrate well before the procedure.
Diagnostics: Pre-treatment blood tests, imaging scans, or biopsies to assess the patient’s condition and suitability.

Procedure Description

  1. Step-by-Step:
    • Assessment and preparation by a nurse or doctor.
    • An intravenous (IV) line is inserted into the patient's vein.
    • Polatuzumab Vedotin is infused slowly through the IV.
    • Monitoring for any immediate side effects.
  2. Tools/Equipment: IV line, infusion pump, and necessary monitoring equipment.
  3. Anesthesia/Sedation: Generally not required unless specified for pain management or comfort.

Duration

The infusion typically takes about 30-90 minutes, depending on dosage and specific patient needs.

Setting

Usually performed in a hospital or an outpatient clinic with facilities for chemotherapy administration.

Personnel

Healthcare professionals involved:

  • Oncologist or Hematologist
  • Oncology Nurse
  • Pharmacist
  • Possibly a medical assistant or technician

Risks and Complications

Common Risks: Fatigue, nausea, peripheral neuropathy, and possible infusion reactions like rash or fever.
Rare Risks: Severe infections, allergic reactions, or organ toxicity. Immediate medical attention is available to manage these complications.

Benefits

Expected Benefits: Reduction in tumor size, symptom relief, potential progression to remission.
Timeframe: Benefits may be noticeable within several weeks to a few months, depending on individual response.

Recovery

Post-Procedure Care: Follow-up appointments to monitor response and side effects, medication for side effect management, possible dietary and activity restrictions.
Recovery Time: Varies; patients may expect some side effects to persist for days to weeks.

Alternatives

Other Options: Alternative chemotherapy regimens, radiotherapy, targeted therapies, or stem cell transplant.
Pros and Cons: Each alternative has different effectiveness, side effect profiles, and suitability depending on the patient's condition.

Patient Experience

During the Procedure: Patients may feel slight discomfort from the IV insertion and possible mild infusion reactions.
After the Procedure: Expect fatigue and possible nausea; pain management strategies and comfort measures will be employed to ease symptoms. Regular follow-ups will be conducted to monitor the patient's health and response to treatment.

Medical Policies and Guidelines for Injection, polatuzumab vedotin-piiq, 1 mg

Related policies from health plans

Similar Codes